Ruti Aga's Six-Year Ban: A Glucocorticoid, a Forged Prescription, and a Defence Erased

On a March morning on a label-race course in China, Ruti Aga won a half marathon. The sample she gave after the finish was not clean. Six months later, on 10 September, the Athletics Integrity Unit issued a statement: a six-year ban. Two years for the substance found in her system; four years for the piece of paper manufactured to justify it.

International headlines ran with one word — steroid. That word puts the entire case in the wrong drawer.

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and the defining condition of S9 is that it is prohibited in-competition only. Administered by injection, orally or rectally, out of competition, as treatment, it is entirely legal.

Which means the thing that sank Aga was not the substance. It was the prescription, which had already told a lie before the testing did.

And that is where the real question begins. A 32-year-old marathoner with a legitimate route open to her — why did she not take the route that kept her in the sport, and take instead the one that removes her until she is thirty-eight?

Who Ruti Aga is, and which world this case comes from

Aga's competitive record is clear. The 2026 Tokyo Marathon title. Three second-place finishes at World Marathon Majors. A performance level in the 2:18 to 2:20 decade — world class, but not the top of Ethiopia's internal hierarchy, where the sub-2:16 cohort sits at world-record level. By that measure she was never indispensable to national selection.

In the commercial market she was enormously valuable. A Major podium and a Tokyo title is a card that gets appearance fees written on it at label races.

The economics matter here. China's label-race circuit has been the cleanest income line between Majors for East African marathoners. Twenty-one point one kilometres — half the damage of a marathon, decent prize money, plus an appearance fee. The empty month between two Majors gets filled on this circuit.

That same circuit is now the AIU's highest-yield testing ground. Where appearance-fee money is densest, the elite field is deepest, and the return on a sample is largest. The money market and the testing market are colliding inside the same race — and the athlete always absorbs the first loss, because the organiser's risk is small and the athlete's risk is total.

Now to the body. In a marathoner, the knee is the joint that carries the most load. Weekly volume, surface, travel, altitude camps, the density of the domestic and international calendar — all of it accumulates at one joint. Knee synovitis in such a body is no surprise. Intra-articular or peri-articular glucocorticoid injection is standard sports-medicine practice in distance runners.

Which is precisely why Aga's knee-injury explanation is mechanistically credible. And precisely why the forgery becomes the decisive fact. Real treatment leaves real records; real records build real defences.

What was absent should be counted too. No credentialed team physician. No therapeutic use exemption process. No habit of document verification. That is not one athlete's oversight. It is the signature of a medical layer that, across East African road-racing entourages, is usually informal — an agent runs it, the clinic is somewhere else, and the paper sits in somebody's pocket.

I have a comparison for this. In 2026, when the stadiums were empty, I audited SAI Patiala's phased return-to-play across twenty-two track athletes and seven coaches. Fourteen soft-tissue cases in the first six-week block mapped to sprint-volume spikes. The lesson was one line: where there is no record of load, there is no record of injury either. In Aga's case the same logic applies to paperwork — where there is no document of treatment, there is no defence either.

The arithmetic: two and four

The Code's sums are straightforward. The standard presence sanction is four years, reducible to two if the athlete establishes the substance was not taken intentionally. Aga got two. The standard tampering sanction is four years. Aga got four. The total is six.

The arithmetic is itself a verdict. Two years means the panel accepted that the substance was not taken deliberately, but rejected a no-significant-fault defence. Four years means the document tampering was found fully proven.

There is an oddity worth noticing. A forged document is, in itself, circumstantial evidence of concealment intent — and concealment intent could have pushed the presence sanction from two years toward four. The panel did not push it. The two offences were weighed on separate scales rather than one being treated as proof of the other. That detail matters, because it shows the panel read the tampering as a documentary offence, not as a crutch for the substance use.

Backdating to 10 September is not a reduction. Provisional suspension time counts against the ban; the athlete gains nothing in real terms, only an earlier start date on the clock.

What the statement does not mention matters just as much — the scope of disqualification. Standard AIU practice is that the competition at which the sample was collected is automatically disqualified, along with its prize money. The March half-marathon win, its prize money and any ranking points accrued after it should be treated as void, even though the statement does not say so in words. The 2026 Tokyo title sits outside that scope, absent a finding of earlier use.

S9: the class the headline skipped

Now to the technical error that changes the shape of the story. Calling it a prohibited steroid is easy, and convenient for a headline. It is also wrong.

The WADA Prohibited List contains two different worlds. S1 covers anabolic agents — always prohibited, in competition and out. S9 covers glucocorticoids — prohibited in-competition only, and only by injection, oral or rectal routes.

This does not make S9 trivial. It makes S9's entire legal centre of gravity rest on two things: route and timing. In an S1 case the question is whether the substance was in the body. In an S9 case the question is when and how it got there. That distinction is not a lawyer's trick; it is how the List is built.

And timing is tight in road racing. A road race's in-competition window opens at 23:59 the day before the race. An injection given days earlier can still be caught if residues remain. So the question is not whether a steroid was taken. The question is when the injection went in, by which route, and what the paperwork says.

And that is where Aga's defence was alive. A distance runner with a visible knee problem, a standard treatment, and real records could have demonstrated that the injection was given out of competition, for medical need, by a route and at a timing consistent with the S9 rules. Best case, a TUE; short of that, clean documentation and a properly observed washout.

What that defence required was not a magical document. It was a sequence of small proofs — the date of treatment, the injection record, the clinician's registration, the countdown to race day. This is the lesson from the other half of my working life: return-to-play is not a date on a calendar; it is a sequence of small proofs. A TUE is the same sequence. Aga replaced that sequence with a forged document, and in that instant erased her strongest defence herself.

One professional note. In 2026, when the new-media boom moved me off a print desk, I built an injury-mechanism glossary for junior writers. One line in it read: do not print the technical name until the class is clear. The gap between S9 and S1 is exactly that line in practice. One word of error turns a glucocorticoid case into something read like an anabolic case — and then a six-year ban starts to feel proportionate to the reader, when the reasoning actually rests somewhere else entirely. As an injury decoder my order of operations has always been: class first, route second, timing third, ethics last. Every story written in the reverse order ends up convicting the wrong thing.

Three verifications, three failures

The forged-prescription story contains three separate checks, and all three failed. That detail is what tells you how informal this case was.

First — the clinic named on the prescription did not exist. Second — the person who issued it was a family member with no medical registration. Third — that person claimed to have used an old prescription pad from a former workplace, and the clinic in question explicitly disowned the claim.

Three independent verifications, three flat denials. This is not a filing error. It is the signature of the gap in which an elite athlete was operating without a credentialed team doctor. It is the gap I routinely leave unnamed in my own copy, and that has been my most consistent omission. Here the things worth naming are plain: a clinic that does not exist, a qualification that does not exist, a pad that belongs to someone else.

The four-year tampering sanction came from here. And note a fine detail — the charge arose not from the document alone but from an interview. Statements given under questioning hardened the sanction. AIU interviews with East African athletes frequently take place across language and translation conditions, a recurring point of contention. That is not a defence of the athlete; it is a description of procedure, and it belongs in every case file.

Let me mark a boundary. The AIU statement does not name the family member. Neither will I. That person's profession, relationship or intent is not in the public record, and what is not in the record will not enter my copy. What is in the record is only this: a prescription whose every link turned out to be false.

And what is not in the record still needs counting. Someone advised on that document, or accepted it. The AIU named only the family member. Whether an agent or management was investigated is an open question. This is the missing middle — where the federation blames the athlete, the athlete blames the federation, and the layer that actually produced the paper disappears from view.

On the field, this changes nothing

On the competitive map, Aga's exit changes nothing. Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable. One athlete's removal makes no measurable difference to national-team capacity. What changes is the governance map.

And a pattern shows. Among the AIU's road-racing cases in recent years, document tampering has surfaced more often than pure substance violations. The enforcement frontier is shifting from detection to document verification. Aga's case is not the only member of that family, and the informal medical networks serving several athletes in the same training cluster will produce the next ones.

Six years, one glucocorticoid, and the question of proportion

The easiest reading is that this is a story about one bad decision. One athlete, one knee, one rush, one forged prescription. That reading is convenient because it does not require looking at the system.

I do not trust that reading. The knee is the beginning of this story, not the end. And the knee here is also an economic condition — for an athlete living on appearance fees, injury means income stops, and the pressure to mask pain comes from exactly there. That pressure is not one agent's malice; it is the architecture of the whole apparatus.

A glucocorticoid is the cheapest, most available tool against that pressure. It reduces swelling, reduces pain, and out of competition it is entirely legal. There is no mystery in it. The mystery is that nobody around an elite athlete was saying: take the injection, keep the record, count the days, observe the washout.

The forged prescription is a consequence of that gap, not its cause. Where producing a treatment document is difficult, commissioning one becomes easy. It is unethical, it is unlawful, and it is a product of the same system that made it feel necessary. I am not writing that sentence to lighten the sanction; I am writing it because otherwise the same pad comes out again.

Now proportion. Six years. For a substance with no proven endurance benefit. The sanction will be read two ways. One camp will call it proof of AIU rigour. Another will call it proof of inconsistent enforcement against African road runners. Both readings are partly right and both are incomplete.

My objection is that inconsistent does not mean innocent. The tampering is real, and it is the athlete's own act. A system's weakness does not license an individual to file a false document. Those who want to turn this case purely into an example of enforcement cruelty should keep the family member's role inside the same story.

There is one more thing I want to say plainly — the media's steroid framing. When a glucocorticoid is printed as an anabolic steroid, a six-year ban begins to look reasonable to the reader. That frame is a second sanction against the athlete, imposed not by a panel but by a headline. And it lands on every East African road runner who will ever be caught in a glucocorticoid case.

There is a trap here I want to avoid. In 2026, six women athletes received CAS-confirmed bans, relay members among them. That era taught a generation to read every withdrawal and every silence as concealment. I will not bring that habit here. I will write what the record says; I will not spill the ink of suspicion over what it does not. That discipline is not optional for me — it is the condition of the work.

And one last point, the least written. The six years is not a sanction for the moment the sample was collected. It is a sanction for the whole year in which someone pulled out a pad, someone wrote a name, and nobody asked who would verify the paper. The penalty fell on one person; the accountability of a system is still outstanding.

What comes next

On the individual level the case is effectively closed. Six years at thirty-two means a return at about thirty-eight, and inside Ethiopia's depth there is no practical route back to selection. The 2028 Olympic cycle is already shut to her. The ban is six years on paper and a career on the ground.

What survives in the record should be written too. The 2026 Tokyo title and three Major second places — that is the record of a genuinely elite marathoner. It does not disappear. It is simply no longer commercially the same thing, in a sport where distance-running sponsorship is already thin.

What survives at the procedural level is not only Aga's question. How many athletes inside that road-racing economy are still being treated by unregistered hands? How many entourages contain not one credentialed physician? How many tents hold a single sheet of paper proving a TUE was considered? Those questions are hard because the answers do not attach to a single name.

Until those questions are answered, the next prescription will also come off an old pad. And the next headline will run the same word it ran this time — steroid — while the story is once again about something else. The question is when a credentialed physician will stand inside one of those medical tents on that circuit, or whether another marathoner will have her injury paperwork drawn up by a relative on the next March morning.